Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Judge: FDA can't police drugs alone
As Eli Lilly went up to bat in the big Zyprexa trial in Alaska, the judge said lawsuits play a vital role in drug safety. Without them, claims of safety problems "might well go unaddressed," Judge Mark Rindner told the court. Evidence the State of Alaska presented over the past two weeks, he said, shows that the FDA "isn't capable of policing this matter."
Why the commentary? After the state rested its case, Lilly asked the judge for an immediate verdict in its favor (a routine step at this stage of a trial). The FDA should be dealing with these matters, not states, the lawyer said. Rindner, of course, begged to differ.
So the case proceeded. Lilly trotted out a couple of experts: One not only questioned the link between Zyprexa and diabetes, but the link between weight gain and diabetes. Another said doctors should have known about the weight gain problems anyway, and that Zyprexa's side effects are far outweighed by its benefits. The drugmaker will continue to tell its side of the Zyprexa story this week. Stay tuned.
- read the story at the Anchorage Daily News
- check out the item at Pharmalot
Related Articles:
Did Lilly chief support off-label promos? Report
Former FDAer: Lilly hid risks for profit. Report
Lilly gears up for Alaska's Zyprexa trial. Report
Lilly strengthens Zyprexa warnings. Report
Comments
At my local clinic the Doctors have stopped prescribing Zyprexa except as a temporary PRN for acute cases only.
WHY? for two reasons:
1) The reason they give it out at all is because it is a fine med where indicated for specific symptoms and does the job very well
2)They stopped it as daily maintenance because they believe in their own hearts that it is the worst offender over the other atypicals AND because their patients refuse to take it on account of all the bad Zyprexa PR
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness


